Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Head and Neck Neoplasms × Morphine × Clear all

Phase

Phase 4 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colonic Neoplasms 3 Chronic Pain 3 Cancer Pain 3 Supratentorial Neoplasms 2 Pain, Postoperative 2 Neoplastic Cells, Circulating 2 Neoplasms 2 Colorectal Neoplasms 2 Substance Withdrawal Syndrome 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Pain 1 Neoplasm, Residual 1 Nalbuphine Allergy 1 Ileus 1 Head and Neck Neoplasms 1 Diverticulosis, Colonic 1 Diverticulitis, Colonic 1 Constipation 1 Breakthrough Pain 1 Brain Neoplasms 1 Agnosia 1 Age Problem 1 Abdominal Cancer 1

Interventions

Cisplatin 4 Fluorouracil 3 Norepinephrine 2 Fentanyl 2 Docetaxel 2 Cetuximab 2 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1 technetium Tc 99m nanocolloid 1 nimotuzumab 1 dopexamine 1 Venlafaxine Hydrochloride 1 Tobacco Use Cessation Devices 1 Taste 1 Saline Solution 1 Radiotherapy, Intensity-Modulated 1 Radiosurgery 1 Psychiatric Rehabilitation 1 Pregabalin 1 Polymerase Chain Reaction 1 Oral Hygiene 1 Neck Dissection 1 Morphine 1 Mitomycin 1 Mirtazapine 1 Methadone 1 Levobupivacaine 1 Gene Expression Profiling 1 Gastrostomy 1 Gabapentin 1 Epinephrine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02869321 2019-05-13

ANTALGIP

Central Hospital, Nancy, France

Phase 4 Completed

Head and Neck Neoplasms, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡